Autos, luxury, pharma and energy face a tariff shock with global spillovers
MARKET INSIDER – A fresh tariff threat from U.S. President Donald Trump is once again jolting global markets—this time with Greenland at the center of a widening transatlantic standoff. By pledging to impose sweeping duties on key European allies as early as February, Trump has reignited fears of a new trade war that could ripple far beyond Europe, reshaping supply chains, earnings forecasts, and investor sentiment worldwide.
Under the plan, exports from the U.K., Denmark, Norway, Sweden, France, Germany, the Netherlands and Finland would face a 10% tariff from Feb. 1, escalating to 25% by June. The move is framed as part of Trump’s renewed push to bring Greenland, a self-governing Danish territory, under U.S. control—an ambition that has triggered emergency talks among European leaders and put retaliation firmly back on the table.
The most immediate casualties would likely be Europe’s auto giants, a sector deeply embedded in globalized supply chains and heavily exposed to the U.S. market. Shares in Volkswagen, BMW and Mercedes-Benz Group slid sharply as investors priced in the risk of higher costs and softer demand. Germany, which runs the largest trade surplus with the U.S. among the targeted countries, stands out as particularly vulnerable—raising fresh questions about Europe’s growth engine at a time when its economy is already under strain.
Luxury brands, long seen as resilient thanks to pricing power and affluent consumers, are also feeling the heat. France—home to LVMH and Kering—is squarely in the tariff crosshairs. While high-end groups can pass on some costs, analysts warn that a broader economic slowdown triggered by trade tensions could eventually dampen even luxury demand, eroding one of Europe’s most profitable export pillars.
Pharmaceuticals may represent the biggest macro risk. Medicines are the European Union’s largest export category to the U.S., with shipments topping €84 billion in the first three quarters of last year. Market leaders such as Novo Nordisk, Roche and Sanofi saw early share price pressure, highlighting how tariffs could quickly spill into healthcare costs, innovation budgets, and transatlantic supply security.
Energy markets add another layer of complexity. While oil and gas exports are not the direct target, the threat of a U.S.–Europe trade war has already weighed on crude prices amid concerns over weaker global demand. Stocks such as Equinor, Shell and TotalEnergies slipped as investors reassessed the knock-on effects across commodities, logistics and capital spending.
The bigger story, however, is not Greenland—it’s the signal this sends to markets. As one fund manager put it, 2026 may mark the year when investors fully price in a U.S. less willing to “play ball” with traditional allies. For global portfolios, the debate is no longer whether tariffs will hurt, but who adapts fastest—and whether this renewed era of economic nationalism accelerates the fragmentation of global trade or sparks the next wave of strategic realignment.
